Head-to-head late-stage clinical trials published on Tuesday showed that a Novartis (NYSE:NVS) drug to treat patients with neovascular age-related macular degeneration doesn’t need to be injected as frequently as a rival drug from competitor Regeneron (NSDQ:REGN).
Analysts reportedly said the data gives Novartis’ treatment, RTH258, a competitive edge compared to its rival therapies.
Get the full story at our sister site, Drug Delivery Business News.